Carmichael Hill & Associates’s Filana Therapeutics FLNA Stock Holding History

Carmichael Hill & Associates’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6	Closed	–	–	832
2021 Q3	$0	Buy	+6	New	+$501	﹤0.01%	815

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Carmichael Hill & Associates's FLNA Position: Q4 2021 in Review

Carmichael Hill & Associates sold out of Filana Therapeutics (FLNA) in Q4 2021, closing a stake of 6 shares.

Carmichael Hill & Associates first reported a position in FLNA in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 171 funds tracked by Wall St. Rank hold FLNA as of Q4 2021.

Carmichael Hill & Associates reported no remaining Filana Therapeutics position as of Q4 2021 after selling out during the quarter.
Carmichael Hill & Associates sold 6 Filana Therapeutics shares in Q4 2021.
Carmichael Hill & Associates first reported a position in Filana Therapeutics in Q3 2021 and held it in 1 quarter.
Carmichael Hill & Associates's Filana Therapeutics position peaked at $0 in Q3 2021.
171 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2021.

Based on Carmichael Hill & Associates's 13F filing for Q4 2021, filed 31 Jan 2022.